ArticleWorld journal of orthopedics2025
Efficacy and safety of pre-emptive tapentadol on pain control in total knee arthroplasty: A randomized, double-blind, placebo-controlled trial.
Article in World journal of orthopedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough opioids and non-steroidal anti-inflammatory drugs are commonly used as preemptive analgesics in total knee arthroplasty (TKA), their side effects are a major concern. Tapentadol, a synthetic opioid analgesic, is noted for its higher potency, lower abuse potential, and better gastrointestinal tolerability compared to traditional opioids. However, its efficacy and safety as preemptive analgesia in TKA have not been evaluated.
aimTo hypothesize that preemptive use of tapentadol significantly reduces postoperative pain and rescue analgesic consumption in TKA patients. Clinically, this may reduce opioid burden and improve recovery protocols.
methodsNinety patients undergoing unilateral TKA were randomized to receive either tapentadol (single dose of 100 mg sustained-release,
resultsThe baseline characteristics of both groups were comparable. The 24-hour VAS scores, the primary outcome, were significantly lower in the tapentadol group median [interquartile range (IQR)] [1.0 (1.0-3.0)] compared to the placebo group [3.5 (2.0-5.0)]. Significant differences in VAS scores were observed at 4 hours, 6 hours, and 12 hours postoperatively (
conclusionA preemptive single dose of 100 mg oral tapentadol is safe, effective, and significantly reduces postoperative pain and rescue analgesic requirements in TKA patients. This approach may reduce opioid dependence and support enhanced recovery protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.